Universal Technical Institute, Inc.
Universal Technical Institute, Inc. UTI Peers
See (UTI) competitors and their performances in Stock Market.
Peer Comparison Table: Education & Training Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| UTI | $35.35 | +0.93% | 1.9B | 33.66 | $1.05 | N/A |
| EDU | $46.84 | -2.38% | 7.7B | 20.37 | $2.30 | +1.24% |
| TAL | $10.62 | +1.14% | 6.4B | 75.86 | $0.14 | N/A |
| LRN | $145.29 | +0.41% | 6.3B | 22.77 | $6.38 | N/A |
| LOPE | $194.20 | +1.92% | 5.5B | 24.40 | $7.96 | N/A |
| ATGE | $128.11 | +0.20% | 4.6B | 21.68 | $5.91 | N/A |
| GHC | $959.82 | +0.25% | 4.2B | 6.80 | $141.09 | +0.74% |
| LAUR | $22.31 | +0.22% | 3.3B | 11.99 | $1.86 | N/A |
| PRDO | $33.00 | -0.81% | 2.2B | 14.67 | $2.25 | +1.58% |
| STRA | $89.41 | -0.21% | 2.2B | 19.23 | $4.65 | +2.69% |
Stock Comparison
UTI vs EDU Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, EDU has a market cap of 7.7B. Regarding current trading prices, UTI is priced at $35.35, while EDU trades at $46.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas EDU's P/E ratio is 20.37. In terms of profitability, UTI's ROE is +0.21%, compared to EDU's ROE of +0.10%. Regarding short-term risk, UTI is less volatile compared to EDU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs TAL Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, TAL has a market cap of 6.4B. Regarding current trading prices, UTI is priced at $35.35, while TAL trades at $10.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas TAL's P/E ratio is 75.86. In terms of profitability, UTI's ROE is +0.21%, compared to TAL's ROE of +0.02%. Regarding short-term risk, UTI is less volatile compared to TAL. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs LRN Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, LRN has a market cap of 6.3B. Regarding current trading prices, UTI is priced at $35.35, while LRN trades at $145.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas LRN's P/E ratio is 22.77. In terms of profitability, UTI's ROE is +0.21%, compared to LRN's ROE of +0.23%. Regarding short-term risk, UTI is more volatile compared to LRN. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.
UTI vs LOPE Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, LOPE has a market cap of 5.5B. Regarding current trading prices, UTI is priced at $35.35, while LOPE trades at $194.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas LOPE's P/E ratio is 24.40. In terms of profitability, UTI's ROE is +0.21%, compared to LOPE's ROE of +0.30%. Regarding short-term risk, UTI is less volatile compared to LOPE. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs ATGE Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, ATGE has a market cap of 4.6B. Regarding current trading prices, UTI is priced at $35.35, while ATGE trades at $128.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas ATGE's P/E ratio is 21.68. In terms of profitability, UTI's ROE is +0.21%, compared to ATGE's ROE of +0.17%. Regarding short-term risk, UTI is more volatile compared to ATGE. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.
UTI vs GHC Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, GHC has a market cap of 4.2B. Regarding current trading prices, UTI is priced at $35.35, while GHC trades at $959.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas GHC's P/E ratio is 6.80. In terms of profitability, UTI's ROE is +0.21%, compared to GHC's ROE of +0.15%. Regarding short-term risk, UTI is less volatile compared to GHC. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs LAUR Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, LAUR has a market cap of 3.3B. Regarding current trading prices, UTI is priced at $35.35, while LAUR trades at $22.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas LAUR's P/E ratio is 11.99. In terms of profitability, UTI's ROE is +0.21%, compared to LAUR's ROE of +0.31%. Regarding short-term risk, UTI is more volatile compared to LAUR. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.
UTI vs PRDO Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, PRDO has a market cap of 2.2B. Regarding current trading prices, UTI is priced at $35.35, while PRDO trades at $33.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas PRDO's P/E ratio is 14.67. In terms of profitability, UTI's ROE is +0.21%, compared to PRDO's ROE of +0.16%. Regarding short-term risk, UTI is more volatile compared to PRDO. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.
UTI vs STRA Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, STRA has a market cap of 2.2B. Regarding current trading prices, UTI is priced at $35.35, while STRA trades at $89.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas STRA's P/E ratio is 19.23. In terms of profitability, UTI's ROE is +0.21%, compared to STRA's ROE of +0.07%. Regarding short-term risk, UTI is less volatile compared to STRA. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs AFYA Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, AFYA has a market cap of 1.6B. Regarding current trading prices, UTI is priced at $35.35, while AFYA trades at $17.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas AFYA's P/E ratio is 13.37. In terms of profitability, UTI's ROE is +0.21%, compared to AFYA's ROE of +0.17%. Regarding short-term risk, UTI is more volatile compared to AFYA. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.
UTI vs GOTU Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, GOTU has a market cap of 1.5B. Regarding current trading prices, UTI is priced at $35.35, while GOTU trades at $4.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas GOTU's P/E ratio is -8.17. In terms of profitability, UTI's ROE is +0.21%, compared to GOTU's ROE of -0.43%. Regarding short-term risk, UTI is more volatile compared to GOTU. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.
UTI vs COUR Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, COUR has a market cap of 1.4B. Regarding current trading prices, UTI is priced at $35.35, while COUR trades at $8.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas COUR's P/E ratio is -20.76. In terms of profitability, UTI's ROE is +0.21%, compared to COUR's ROE of -0.11%. Regarding short-term risk, UTI is less volatile compared to COUR. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs KLC Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, KLC has a market cap of 1.4B. Regarding current trading prices, UTI is priced at $35.35, while KLC trades at $11.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas KLC's P/E ratio is -20.15. In terms of profitability, UTI's ROE is +0.21%, compared to KLC's ROE of -0.13%. Regarding short-term risk, UTI is less volatile compared to KLC. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs UDMY Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, UDMY has a market cap of 1.1B. Regarding current trading prices, UTI is priced at $35.35, while UDMY trades at $7.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas UDMY's P/E ratio is -16.89. In terms of profitability, UTI's ROE is +0.21%, compared to UDMY's ROE of -0.32%. Regarding short-term risk, UTI is less volatile compared to UDMY. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs DAO Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, DAO has a market cap of 1.1B. Regarding current trading prices, UTI is priced at $35.35, while DAO trades at $8.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas DAO's P/E ratio is 52.76. In terms of profitability, UTI's ROE is +0.21%, compared to DAO's ROE of -0.04%. Regarding short-term risk, UTI is less volatile compared to DAO. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs ARCE Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, ARCE has a market cap of 927.4M. Regarding current trading prices, UTI is priced at $35.35, while ARCE trades at $13.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas ARCE's P/E ratio is -73.58. In terms of profitability, UTI's ROE is +0.21%, compared to ARCE's ROE of +0.02%. Regarding short-term risk, UTI is more volatile compared to ARCE. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.
UTI vs REDU Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, REDU has a market cap of 730.3M. Regarding current trading prices, UTI is priced at $35.35, while REDU trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas REDU's P/E ratio is -23.04. In terms of profitability, UTI's ROE is +0.21%, compared to REDU's ROE of +0.15%. Regarding short-term risk, UTI is less volatile compared to REDU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs LINC Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, LINC has a market cap of 728.2M. Regarding current trading prices, UTI is priced at $35.35, while LINC trades at $23.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas LINC's P/E ratio is 59.10. In terms of profitability, UTI's ROE is +0.21%, compared to LINC's ROE of +0.07%. Regarding short-term risk, UTI is more volatile compared to LINC. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.
UTI vs APEI Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, APEI has a market cap of 510.2M. Regarding current trading prices, UTI is priced at $35.35, while APEI trades at $28.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas APEI's P/E ratio is 27.73. In terms of profitability, UTI's ROE is +0.21%, compared to APEI's ROE of +0.08%. Regarding short-term risk, UTI is less volatile compared to APEI. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs QSG Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, QSG has a market cap of 341.4M. Regarding current trading prices, UTI is priced at $35.35, while QSG trades at $6.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas QSG's P/E ratio is 6.36. In terms of profitability, UTI's ROE is +0.21%, compared to QSG's ROE of +0.78%. Regarding short-term risk, UTI is less volatile compared to QSG. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs VSTA Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, VSTA has a market cap of 336M. Regarding current trading prices, UTI is priced at $35.35, while VSTA trades at $4.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas VSTA's P/E ratio is 4.23. In terms of profitability, UTI's ROE is +0.21%, compared to VSTA's ROE of +0.10%. Regarding short-term risk, UTI is more volatile compared to VSTA. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.
UTI vs VTRU Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, VTRU has a market cap of 304.2M. Regarding current trading prices, UTI is priced at $35.35, while VTRU trades at $9.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas VTRU's P/E ratio is 15.91. In terms of profitability, UTI's ROE is +0.21%, compared to VTRU's ROE of -0.01%. Regarding short-term risk, UTI is more volatile compared to VTRU. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.
UTI vs RYET Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, RYET has a market cap of 258.2M. Regarding current trading prices, UTI is priced at $35.35, while RYET trades at $7.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas RYET's P/E ratio is -255.00. In terms of profitability, UTI's ROE is +0.21%, compared to RYET's ROE of -1.59%. Regarding short-term risk, UTI is less volatile compared to RYET. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs CHGG Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, CHGG has a market cap of 175.8M. Regarding current trading prices, UTI is priced at $35.35, while CHGG trades at $1.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas CHGG's P/E ratio is -0.21. In terms of profitability, UTI's ROE is +0.21%, compared to CHGG's ROE of -3.67%. Regarding short-term risk, UTI is less volatile compared to CHGG. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs SKIL Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, SKIL has a market cap of 152.2M. Regarding current trading prices, UTI is priced at $35.35, while SKIL trades at $17.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas SKIL's P/E ratio is -1.21. In terms of profitability, UTI's ROE is +0.21%, compared to SKIL's ROE of -0.91%. Regarding short-term risk, UTI is less volatile compared to SKIL. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs LGCY Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, LGCY has a market cap of 118M. Regarding current trading prices, UTI is priced at $35.35, while LGCY trades at $9.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas LGCY's P/E ratio is 16.15. In terms of profitability, UTI's ROE is +0.21%, compared to LGCY's ROE of +1.07%. Regarding short-term risk, UTI is less volatile compared to LGCY. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs STG Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, STG has a market cap of 80.2M. Regarding current trading prices, UTI is priced at $35.35, while STG trades at $5.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas STG's P/E ratio is 1.91. In terms of profitability, UTI's ROE is +0.21%, compared to STG's ROE of +0.67%. Regarding short-term risk, UTI is less volatile compared to STG. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs KIDZ Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, KIDZ has a market cap of 64.2M. Regarding current trading prices, UTI is priced at $35.35, while KIDZ trades at $3.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas KIDZ's P/E ratio is -124.67. In terms of profitability, UTI's ROE is +0.21%, compared to KIDZ's ROE of +0.16%. Regarding short-term risk, UTI is less volatile compared to KIDZ. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs ONE Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, ONE has a market cap of 51.3M. Regarding current trading prices, UTI is priced at $35.35, while ONE trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas ONE's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.21%, compared to ONE's ROE of -1.90%. Regarding short-term risk, UTI is less volatile compared to ONE. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs GNS Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, GNS has a market cap of 30M. Regarding current trading prices, UTI is priced at $35.35, while GNS trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas GNS's P/E ratio is -0.41. In terms of profitability, UTI's ROE is +0.21%, compared to GNS's ROE of -0.14%. Regarding short-term risk, UTI is less volatile compared to GNS. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs IH Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, IH has a market cap of 24.2M. Regarding current trading prices, UTI is priced at $35.35, while IH trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas IH's P/E ratio is 9.40. In terms of profitability, UTI's ROE is +0.21%, compared to IH's ROE of +0.11%. Regarding short-term risk, UTI is less volatile compared to IH. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs BTCT Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, BTCT has a market cap of 21.1M. Regarding current trading prices, UTI is priced at $35.35, while BTCT trades at $3.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas BTCT's P/E ratio is -4.97. In terms of profitability, UTI's ROE is +0.21%, compared to BTCT's ROE of -0.08%. Regarding short-term risk, UTI is less volatile compared to BTCT. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs AIU Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, AIU has a market cap of 18.8M. Regarding current trading prices, UTI is priced at $35.35, while AIU trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas AIU's P/E ratio is 0.51. In terms of profitability, UTI's ROE is +0.21%, compared to AIU's ROE of -1.90%. Regarding short-term risk, UTI is less volatile compared to AIU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs GEHI Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, GEHI has a market cap of 18.3M. Regarding current trading prices, UTI is priced at $35.35, while GEHI trades at $13.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas GEHI's P/E ratio is -0.24. In terms of profitability, UTI's ROE is +0.21%, compared to GEHI's ROE of -0.90%. Regarding short-term risk, UTI is less volatile compared to GEHI. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs YQ Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, YQ has a market cap of 18.1M. Regarding current trading prices, UTI is priced at $35.35, while YQ trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas YQ's P/E ratio is -0.62. In terms of profitability, UTI's ROE is +0.21%, compared to YQ's ROE of -0.46%. Regarding short-term risk, UTI is less volatile compared to YQ. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs EDTK Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, EDTK has a market cap of 15.3M. Regarding current trading prices, UTI is priced at $35.35, while EDTK trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas EDTK's P/E ratio is -2.00. In terms of profitability, UTI's ROE is +0.21%, compared to EDTK's ROE of -0.36%. Regarding short-term risk, UTI is less volatile compared to EDTK. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs BEDU Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, BEDU has a market cap of 13.4M. Regarding current trading prices, UTI is priced at $35.35, while BEDU trades at $1.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas BEDU's P/E ratio is -0.44. In terms of profitability, UTI's ROE is +0.21%, compared to BEDU's ROE of -1.61%. Regarding short-term risk, UTI is more volatile compared to BEDU. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.
UTI vs AACG Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, AACG has a market cap of 13.4M. Regarding current trading prices, UTI is priced at $35.35, while AACG trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas AACG's P/E ratio is -6.06. In terms of profitability, UTI's ROE is +0.21%, compared to AACG's ROE of -0.43%. Regarding short-term risk, UTI is less volatile compared to AACG. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs TEDU Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, TEDU has a market cap of 12.2M. Regarding current trading prices, UTI is priced at $35.35, while TEDU trades at $1.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas TEDU's P/E ratio is -2.40. In terms of profitability, UTI's ROE is +0.21%, compared to TEDU's ROE of -0.05%. Regarding short-term risk, UTI is less volatile compared to TEDU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs JZ Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, JZ has a market cap of 11.3M. Regarding current trading prices, UTI is priced at $35.35, while JZ trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas JZ's P/E ratio is -2.00. In terms of profitability, UTI's ROE is +0.21%, compared to JZ's ROE of -846.41%. Regarding short-term risk, UTI is less volatile compared to JZ. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs VSA Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, VSA has a market cap of 10.4M. Regarding current trading prices, UTI is priced at $35.35, while VSA trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas VSA's P/E ratio is -0.14. In terms of profitability, UTI's ROE is +0.21%, compared to VSA's ROE of -0.01%. Regarding short-term risk, UTI is less volatile compared to VSA. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs VEDU Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, VEDU has a market cap of 9.3M. Regarding current trading prices, UTI is priced at $35.35, while VEDU trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas VEDU's P/E ratio is -1.91. In terms of profitability, UTI's ROE is +0.21%, compared to VEDU's ROE of -0.43%. Regarding short-term risk, UTI is less volatile compared to VEDU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs GV Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, GV has a market cap of 9M. Regarding current trading prices, UTI is priced at $35.35, while GV trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas GV's P/E ratio is -1.54. In terms of profitability, UTI's ROE is +0.21%, compared to GV's ROE of -0.57%. Regarding short-term risk, UTI is less volatile compared to GV. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs EEIQ Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, EEIQ has a market cap of 7.1M. Regarding current trading prices, UTI is priced at $35.35, while EEIQ trades at $0.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas EEIQ's P/E ratio is -1.15. In terms of profitability, UTI's ROE is +0.21%, compared to EEIQ's ROE of -0.98%. Regarding short-term risk, UTI is less volatile compared to EEIQ. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs WAFU Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, WAFU has a market cap of 6.4M. Regarding current trading prices, UTI is priced at $35.35, while WAFU trades at $1.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas WAFU's P/E ratio is -8.06. In terms of profitability, UTI's ROE is +0.21%, compared to WAFU's ROE of -0.10%. Regarding short-term risk, UTI is less volatile compared to WAFU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs GSUN Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, GSUN has a market cap of 6M. Regarding current trading prices, UTI is priced at $35.35, while GSUN trades at $3.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas GSUN's P/E ratio is -1.61. In terms of profitability, UTI's ROE is +0.21%, compared to GSUN's ROE of -2.21%. Regarding short-term risk, UTI is less volatile compared to GSUN. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs TCTM Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, TCTM has a market cap of 4.9M. Regarding current trading prices, UTI is priced at $35.35, while TCTM trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas TCTM's P/E ratio is -0.15. In terms of profitability, UTI's ROE is +0.21%, compared to TCTM's ROE of -0.01%. Regarding short-term risk, UTI is less volatile compared to TCTM. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs TWOU Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, TWOU has a market cap of 4.4M. Regarding current trading prices, UTI is priced at $35.35, while TWOU trades at $1.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas TWOU's P/E ratio is -0.01. In terms of profitability, UTI's ROE is +0.21%, compared to TWOU's ROE of -14.93%. Regarding short-term risk, UTI is less volatile compared to TWOU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs MYND Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, MYND has a market cap of 4.1M. Regarding current trading prices, UTI is priced at $35.35, while MYND trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas MYND's P/E ratio is -0.38. In terms of profitability, UTI's ROE is +0.21%, compared to MYND's ROE of -1.26%. Regarding short-term risk, UTI is less volatile compared to MYND. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs CLEU Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, CLEU has a market cap of 3.5M. Regarding current trading prices, UTI is priced at $35.35, while CLEU trades at $1.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas CLEU's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.21%, compared to CLEU's ROE of -0.13%. Regarding short-term risk, UTI is less volatile compared to CLEU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs KIDZW Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, KIDZW has a market cap of 3.2M. Regarding current trading prices, UTI is priced at $35.35, while KIDZW trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas KIDZW's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.21%, compared to KIDZW's ROE of +0.16%. Regarding short-term risk, UTI is less volatile compared to KIDZW. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs METX Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, METX has a market cap of 3.1M. Regarding current trading prices, UTI is priced at $35.35, while METX trades at $2.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas METX's P/E ratio is 0.79. In terms of profitability, UTI's ROE is +0.21%, compared to METX's ROE of -0.08%. Regarding short-term risk, UTI is less volatile compared to METX. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs ASPU Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, ASPU has a market cap of 2.6M. Regarding current trading prices, UTI is priced at $35.35, while ASPU trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas ASPU's P/E ratio is -0.26. In terms of profitability, UTI's ROE is +0.21%, compared to ASPU's ROE of -0.42%. Regarding short-term risk, UTI is less volatile compared to ASPU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs COE Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, COE has a market cap of 2.2M. Regarding current trading prices, UTI is priced at $35.35, while COE trades at $24.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas COE's P/E ratio is -19.13. In terms of profitability, UTI's ROE is +0.21%, compared to COE's ROE of +0.51%. Regarding short-term risk, UTI is more volatile compared to COE. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.
UTI vs LXEH Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, LXEH has a market cap of 2.2M. Regarding current trading prices, UTI is priced at $35.35, while LXEH trades at $1.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas LXEH's P/E ratio is -0.65. In terms of profitability, UTI's ROE is +0.21%, compared to LXEH's ROE of -0.64%. Regarding short-term risk, UTI is less volatile compared to LXEH. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs FEDU Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, FEDU has a market cap of 2.1M. Regarding current trading prices, UTI is priced at $35.35, while FEDU trades at $9.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas FEDU's P/E ratio is 97.65. In terms of profitability, UTI's ROE is +0.21%, compared to FEDU's ROE of +0.00%. Regarding short-term risk, UTI is less volatile compared to FEDU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs RYB Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, RYB has a market cap of 1M. Regarding current trading prices, UTI is priced at $35.35, while RYB trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas RYB's P/E ratio is 1.87. In terms of profitability, UTI's ROE is +0.21%, compared to RYB's ROE of +0.05%. Regarding short-term risk, UTI is less volatile compared to RYB. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs AMBO Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, AMBO has a market cap of 374.2K. Regarding current trading prices, UTI is priced at $35.35, while AMBO trades at $2.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas AMBO's P/E ratio is 23.82. In terms of profitability, UTI's ROE is +0.21%, compared to AMBO's ROE of +0.21%. Regarding short-term risk, UTI is less volatile compared to AMBO. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs BTCTW Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, BTCTW has a market cap of 13.6K. Regarding current trading prices, UTI is priced at $35.35, while BTCTW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas BTCTW's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.21%, compared to BTCTW's ROE of -0.08%. Regarding short-term risk, UTI is less volatile compared to BTCTW. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs FHS Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, FHS has a market cap of 0. Regarding current trading prices, UTI is priced at $35.35, while FHS trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas FHS's P/E ratio is 0.55. In terms of profitability, UTI's ROE is +0.21%, compared to FHS's ROE of N/A. Regarding short-term risk, UTI is less volatile compared to FHS. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs ZVO Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, ZVO has a market cap of 0. Regarding current trading prices, UTI is priced at $35.35, while ZVO trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas ZVO's P/E ratio is -0.08. In terms of profitability, UTI's ROE is +0.21%, compared to ZVO's ROE of -1.07%. Regarding short-term risk, UTI is less volatile compared to ZVO. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs NEW Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, NEW has a market cap of 0. Regarding current trading prices, UTI is priced at $35.35, while NEW trades at $1.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas NEW's P/E ratio is -0.55. In terms of profitability, UTI's ROE is +0.21%, compared to NEW's ROE of -0.09%. Regarding short-term risk, UTI is less volatile compared to NEW. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs HMHC Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, HMHC has a market cap of 0. Regarding current trading prices, UTI is priced at $35.35, while HMHC trades at $21.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas HMHC's P/E ratio is 12.54. In terms of profitability, UTI's ROE is +0.21%, compared to HMHC's ROE of +0.01%. Regarding short-term risk, UTI is more volatile compared to HMHC. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.
UTI vs HLG Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, HLG has a market cap of 0. Regarding current trading prices, UTI is priced at $35.35, while HLG trades at $14.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas HLG's P/E ratio is 5.29. In terms of profitability, UTI's ROE is +0.21%, compared to HLG's ROE of +0.11%. Regarding short-term risk, UTI is more volatile compared to HLG. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.
UTI vs ZME Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, ZME has a market cap of 0. Regarding current trading prices, UTI is priced at $35.35, while ZME trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas ZME's P/E ratio is -0.00. In terms of profitability, UTI's ROE is +0.21%, compared to ZME's ROE of -1.88%. Regarding short-term risk, UTI is less volatile compared to ZME. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.
UTI vs GPX Comparison
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.9B. In comparison, GPX has a market cap of 0. Regarding current trading prices, UTI is priced at $35.35, while GPX trades at $20.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 33.66, whereas GPX's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.21%, compared to GPX's ROE of +0.03%. Regarding short-term risk, UTI is more volatile compared to GPX. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.